Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) accounts for 8–10% of end-stage chronic kidney disease (CKD) patients worldwide. In the last decade, the advanced knowledge in genetics and molecular pathobiology of ADPKD focused some aberrant molecular pathways involved in the pathog...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisani, Antonio, Riccio, Eleonora, Bruzzese, Dario, Sabbatini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196463/
https://www.ncbi.nlm.nih.gov/pubmed/30348113
http://dx.doi.org/10.1186/s12882-018-1090-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196463/
https://www.ncbi.nlm.nih.gov/pubmed/30348113
http://dx.doi.org/10.1186/s12882-018-1090-3

Ejemplares similares